Literature DB >> 31676828

LSD1-mediated repression of GFI1 super-enhancer plays an essential role in erythroleukemia.

Goichi Tatsumi1,2, Masahiro Kawahara3, Ryusuke Yamamoto1, Masakatsu Hishizawa1, Katsuyuki Kito2, Takayoshi Suzuki4,5, Akifumi Takaori-Kondo1, Akira Andoh2.   

Abstract

Super-enhancers (SEs) consist of enhancer clusters with abundant binding of transcription factors (TFs) and cofactors. LSD1 is a histone modifier that eliminates SE activity. However, whether SE suppression by LSD1 is associated with leukemogenesis remains unknown. In erythro-megakaryocyte lineage leukemia cells, activation of the SE of GFI1 (GFI1-SE) is related to induction of myeloid differentiation by LSD1 inhibitors NCD38 and NCD25 and to their antileukemia effect. Although functional TF-motifs were concentrated in an evolutionally conserved area, NCD38 barely induced additional TF recruitment. Instead, the transcription cofactors including LSD1, CoREST, HDAC1, and HDAC2 were evicted from GFI1-SE. Deletion of GFI1-SE impaired induction of myeloid differentiation by NCD38 and NCD25 in erythroleukemia cells. Gene set enrichment analysis revealed that the GFI1-SE deletion impaired NCD38-induced programs related to granulocyte differentiation and the CEBPA network, but restored NCD38-suppressed programs related to erythroid development, GATA1 targets, and acute myeloid leukemia (AML) clusters including FAB subtype M6 and AML with myelodysplastic syndrome-related chromosomal abnormalities. Ontologies of genes whose expression changes by NCD38 were canceled due to the GFI1-SE deletion showed enrichment in AML and neutropenia signatures. Collectively, our data suggest that sustainable repression of GFI1-SE by LSD1 is essential for sustenance of erythroleukemia cells.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31676828     DOI: 10.1038/s41375-019-0614-6

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

1.  Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants.

Authors:  Stephen C J Parker; Michael L Stitzel; D Leland Taylor; Jose Miguel Orozco; Michael R Erdos; Jennifer A Akiyama; Kelly Lammerts van Bueren; Peter S Chines; Narisu Narisu; Brian L Black; Axel Visel; Len A Pennacchio; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

2.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.

Authors:  Denes Hnisz; Jurian Schuijers; Charles Y Lin; Abraham S Weintraub; Brian J Abraham; Tong Ihn Lee; James E Bradner; Richard A Young
Journal:  Mol Cell       Date:  2015-03-19       Impact factor: 17.970

4.  MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis.

Authors:  Beatriz Aranda-Orgilles; Ricardo Saldaña-Meyer; Eric Wang; Eirini Trompouki; Anne Fassl; Stephanie Lau; Jasper Mullenders; Pedro P Rocha; Ramya Raviram; María Guillamot; María Sánchez-Díaz; Kun Wang; Clarisse Kayembe; Nan Zhang; Leonela Amoasii; Avik Choudhuri; Jane A Skok; Markus Schober; Danny Reinberg; Piotr Sicinski; Heinrich Schrewe; Aristotelis Tsirigos; Leonard I Zon; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2016-08-25       Impact factor: 24.633

5.  Master transcription factors and mediator establish super-enhancers at key cell identity genes.

Authors:  Warren A Whyte; David A Orlando; Denes Hnisz; Brian J Abraham; Charles Y Lin; Michael H Kagey; Peter B Rahl; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

Review 6.  Modification of enhancer chromatin: what, how, and why?

Authors:  Eliezer Calo; Joanna Wysocka
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

Review 7.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

8.  Immunogenetics. Chromatin state dynamics during blood formation.

Authors:  David Lara-Astiaso; Assaf Weiner; Erika Lorenzo-Vivas; Irina Zaretsky; Diego Adhemar Jaitin; Eyal David; Hadas Keren-Shaul; Alexander Mildner; Deborah Winter; Steffen Jung; Nir Friedman; Ido Amit
Journal:  Science       Date:  2014-08-07       Impact factor: 47.728

9.  Characterization of transcriptional networks in blood stem and progenitor cells using high-throughput single-cell gene expression analysis.

Authors:  Victoria Moignard; Iain C Macaulay; Gemma Swiers; Florian Buettner; Judith Schütte; Fernando J Calero-Nieto; Sarah Kinston; Anagha Joshi; Rebecca Hannah; Fabian J Theis; Sten Eirik Jacobsen; Marella F de Bruijn; Berthold Göttgens
Journal:  Nat Cell Biol       Date:  2013-03-24       Impact factor: 28.824

10.  A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.

Authors:  Daniel Herranz; Alberto Ambesi-Impiombato; Teresa Palomero; Stephanie A Schnell; Laura Belver; Agnieszka A Wendorff; Luyao Xu; Mireia Castillo-Martin; David Llobet-Navás; Carlos Cordon-Cardo; Emmanuelle Clappier; Jean Soulier; Adolfo A Ferrando
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

View more
  5 in total

Review 1.  Super-Enhancers, Phase-Separated Condensates, and 3D Genome Organization in Cancer.

Authors:  Seng Chuan Tang; Udhaya Vijayakumar; Ying Zhang; Melissa Jane Fullwood
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

2.  Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.

Authors:  Warren Fiskus; Christopher P Mill; Behnam Nabet; Dimuthu Perera; Christine Birdwell; Taghi Manshouri; Bernardo Lara; Tapan M Kadia; Courtney DiNardo; Koichi Takahashi; Naval Daver; Prithviraj Bose; Lucia Masarova; Naveen Pemmaraju; Steven Kornblau; Gautam Borthakur; Guillermo Montalban-Bravo; Guillermo Garcia Manero; Sunil Sharma; Matthew Stubbs; Xiaoping Su; Michael R Green; Cristian Coarfa; Srdan Verstovsek; Joseph D Khoury; Christopher R Vakoc; Kapil N Bhalla
Journal:  Blood Cancer J       Date:  2021-05-20       Impact factor: 9.812

3.  Discovery of orally active chalcones as histone lysine specific demethylase 1 inhibitors for the treatment of leukaemia.

Authors:  Yang Li; Ying Sun; Yang Zhou; Xinyang Li; Huan Zhang; Guojun Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 4.  Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A.

Authors:  Chao Yang; Dan Li; Shaohong Zang; Lei Zhang; Zhangfeng Zhong; Yingtang Zhou
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

5.  Integrative analysis reveals histone demethylase LSD1 promotes RNA polymerase II pausing.

Authors:  Hani Jieun Kim; Pishun Li; Taiyun Kim; Andrew J Oldfield; Xiaofeng Zheng; Pengyi Yang
Journal:  iScience       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.